Sulbactam/Ampicillin versus Cefoxitin in the Treatment of Obstetric and Gynaecological Infections

Senft, H.H.; Stiglmayer, R.; Eibach, H. W.; Koerner, H.G.

doi:10.2165/00003495-198600312-00005

Cited by 15 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This combination has also been used prophylactically in surgical procedures and appears to have efficacy similar to that of alternative antibiotic regimens (39). An ampicillin-sulbactam regimen has been favorably compared with treatment with cefoxitin in acute salpingitis (27) and other obstetric and gynecological infections (131).…”

Section: Sulbactammentioning

confidence: 99%

Beta-lactamase inhibitors from laboratory to clinic.

Bush

1988

Clinical Microbiology Reviews

View full text Add to dashboard Cite

Section: Sulbactammentioning

confidence: 99%

Beta-lactamase inhibitors from laboratory to clinic.

Bush

1988

Clinical Microbiology Reviews

View full text Add to dashboard Cite

“…Small sample size may have compromised the authors' ability to identify potential differences. 57 Pediatric Meningitis. In pediatric patients, ampicillin 400 mg/kg/d plus either sulbactam 50 mg/kg/d or chloramphenicol 100 mg/kg/d iv for at least ten days was used to treat bacterial meningitis.…”

Section: Treatment Of Infectionsmentioning

confidence: 99%

Sulbactam/Ampicillin, a New Beta-Lactamase Inhibitor/Beta-Lactam Antibiotic Combination

Benson¹,

Nahata²

1988

Drug Intelligence & Clinical Pharmacy

View full text Add to dashboard Cite

Sulbactam/ampicillin is a combination of a beta-lactamase inhibitor with minimal intrinsic antibacterial activity (sulbactam sodium), and an aminopenicillin (ampicillin sodium). The addition of sulbactam to ampicillin has no effect on the chemical stability of ampicillin in aqueous solution, and the administration guidelines of the combination are the same as for ampicillin alone. Sulbactam acts primarily by irreversible inactivation of beta-lactamases from most beta-lactamase-producing organisms. The pharmacokinetics of sulbactam are similar to those of ampicillin with an elimination half-life of about one hour in most patients. One difference is that serum and tissue concentrations of sulbactam are usually twice those of ampicillin, at equivalent doses. The sulbactam/ampicillin combination has been approved for the treatment of adults with intraabdominal, skin and skin structure, and gynecological infections due to beta-lactamase-producing bacteria such as Staphylococcus aureus, Escherichia coli, and species of Klebsiella and Bacteroides. Clinical studies to date have also shown the combination to be effective for the treatment of meningitis, pneumonia, gonorrhea, epiglottis, urinary tract infections, cervical adenitis, and as prophylaxis for abdominal and gynecological surgeries. Many of these studies, however, have included small numbers of patients and/or had design flaws. Adverse effects have been minor with most being attributed to the ampicillin component. Sulbactam/ampicillin compares favorably with other antibiotic regimens in terms of acquisition costs and ease of administration.

show abstract